COLL

Business Context and Reporting Period

Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Collegium is a biopharmaceutical company focused on pain management and ADHD. Its portfolio includes Jornay PM (ADHD), Belbuca, Xtampza ER, Nucynta ER/IR (pain), and Symproic (opioid-induced constipation). The company's financial results for the period are significantly influenced by the September 2024 acquisition of Ironshore Therapeutics, which added Jornay PM to its portfolio.

Key Financial Metrics

Note: Total Debt includes $581.3 million in Term Notes and $241.5 million in Convertible Senior Notes.

Material Changes vs. Prior Period

• Revenue Growth: Net product revenues increased 31.4% in Q3 2025 and 28.0% in the nine-month period compared to 2024. The primary driver was the inclusion of Jornay PM revenue following the Ironshore acquisition, contributing $33.8 million in Q3 and $95.0 million in the nine-month period.
• Profitability: Net income for Q3 2025 rose to $31.5 million from $9.3 million in Q3 2024. However, nine-month net income decreased to $45.9 million from $56.7 million in 2024, largely due to one-time debt extinguishment losses in the prior year and higher operating expenses in the current year.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased significantly ($67.1 million in Q3 2025 vs. $62.0 million in Q3 2024) due to added headcount and sales force expansion for Jornay PM. Acquisition-related expenses decreased as the Ironshore transaction closed in the prior year.
• Intangible Amortization: Amortization expense increased to $55.5 million in Q3 2025 from $40.8 million in Q3 2024, reflecting the full quarter of amortization for assets acquired from Ironshore.

Guidance, Outlook, and Risks

• Liquidity: As of September 30, 2025, the company held $285.9 million in cash, cash equivalents, and marketable securities. Management believes this, combined with operating cash flows, is sufficient to fund operations and debt service for the foreseeable future.
• Share Repurchases: The 2024-2025 repurchase program expired in June 2025. A new program was authorized in July 2025 for up to $150 million through December 31, 2026. No shares have been repurchased under the new program as of the filing date.
• Debt Obligations: The company has substantial indebtedness, including a $645.8 million Term Loan (maturity 2029) and $241.5 million in Convertible Notes (maturity 2029). The Term Loan bears a variable interest rate (SOFR + 4.50%) and requires quarterly amortization payments.
• Key Risks:
  • Regulatory & Litigation: Ongoing patent litigation with Purdue (Xtampza ER, Nucynta) and generic competitors (Alvogen, Chemo Research) regarding Belbuca. Potential for FDA labeling changes regarding abuse-deterrent claims.
  • Supply Chain: Reliance on sole suppliers for active pharmaceutical ingredients (APIs), particularly for Jornay PM (methylphenidate), which has faced industry-wide shortages.
  • Market Dynamics: Competition from new non-opioid analgesics (e.g., Vertex's suzetrigine) and potential pricing pressures from government legislation.

Investor Verification Checklist

• Jornay PM Performance: Verify the sustainability of Jornay PM revenue growth and the impact of potential methylphenidate supply chain constraints.
• Debt Service Capacity: Assess the company's ability to meet quarterly amortization payments on the Term Loan and interest obligations given the variable rate environment.
• Patent Litigation Status: Monitor the outcomes of pending litigation with Purdue and generic entrants for Belbuca, as adverse rulings could threaten core revenue streams.
• Rebate and Return Estimates: Review the accuracy of gross-to-net adjustments, as significant changes in rebate or return estimates can materially impact net revenue.
• Share Repurchase Execution: Track the utilization of the new $150 million share repurchase program and its impact on cash reserves.